Involvement of dopaminergic system in phencyclidine-induced place preference in mice pretreated with phencyclidine repeatedly

Yukihiro Noda, Yoshiaki Miyamoto, Takayoshi Mamiya, Hiroyuki Kamei, Hiroshi Furukawa, Toshitaka Nabeshima

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

In the conditioned place preference test, phencyclidine (PCP) produces place aversion in naive rats, whereas PCP produces place preference in rats treated with PCP repeatedly. Although the PCP-induced place aversion is thought to involve the serotonergic system, the mechanisms of the PCP- induced place preference are unclear. We investigated whether the dopaminergic system is involved in place preference induced by PCP in mice repeatedly treated with PCP, because it is well known that the dopaminergic system plays an important role in the rewarding effect of drugs. PCP (2-8 mg/kg s.c.) induced a dose-dependent place aversion in naive mice, whereas PCP (2-8 mg/kg s.c.) induced a dose-dependent place preference in mice pretreated with PCP (10 mg/kg/day s.c.) for 28 days. The place preference induced by PCP (8 mg/kg s.c.) was attenuated significantly by α-methyl-p- tyrosine (100 mg/kg i.p.), a tyrosine hydroxylase inhibitor, 6- hydroxydopamine (100 μg/ mouse i.c.v.), a dopaminergic neurotoxin, and R- (+)-7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine (0.5 mg/kg s.c.), a dopamine D1 receptor antagonist. These agents themselves produced neither the place preference nor aversion. In contrast to the attenuating effects of these agents, N-(2-chloroethyl)-N-ethyl-2- bromobenzylamine (30 mg/kg i.p.), a noradrenergic neurotoxin, ritanserin (1 mg/kg i.p.), a serotonin2 receptor antagonist, and (-) sulpiride (50 and 100 mg/kg i.p.), a dopamine D2 receptor antagonist, failed to affect the PCP- induced place preference. In mice pretreated with methamphetamine (1 mg/kg/day s.c.) for 14 days, PCP (8 mg/kg s.c.) induced the place preference, but not aversion. These results demonstrate that the PCP-induced place preference depends on dopaminergic, but not on serotonergic and noradrenergic, neuronal systems and suggest a role for D1 receptors in the mediation of the PCP-induced place preference.

Original languageEnglish
Pages (from-to)44-51
Number of pages8
JournalJournal of Pharmacology and Experimental Therapeutics
Volume286
Issue number1
Publication statusPublished - 01-07-1998
Externally publishedYes

Fingerprint

Phencyclidine
Neurotoxins
Ritanserin
Dopamine D1 Receptors
Sulpiride
Dopamine Antagonists
Methamphetamine
Oxidopamine
Tyrosine 3-Monooxygenase

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Pharmacology

Cite this

Noda, Yukihiro ; Miyamoto, Yoshiaki ; Mamiya, Takayoshi ; Kamei, Hiroyuki ; Furukawa, Hiroshi ; Nabeshima, Toshitaka. / Involvement of dopaminergic system in phencyclidine-induced place preference in mice pretreated with phencyclidine repeatedly. In: Journal of Pharmacology and Experimental Therapeutics. 1998 ; Vol. 286, No. 1. pp. 44-51.
@article{5cddd73e993941519427a0fa0220ab23,
title = "Involvement of dopaminergic system in phencyclidine-induced place preference in mice pretreated with phencyclidine repeatedly",
abstract = "In the conditioned place preference test, phencyclidine (PCP) produces place aversion in naive rats, whereas PCP produces place preference in rats treated with PCP repeatedly. Although the PCP-induced place aversion is thought to involve the serotonergic system, the mechanisms of the PCP- induced place preference are unclear. We investigated whether the dopaminergic system is involved in place preference induced by PCP in mice repeatedly treated with PCP, because it is well known that the dopaminergic system plays an important role in the rewarding effect of drugs. PCP (2-8 mg/kg s.c.) induced a dose-dependent place aversion in naive mice, whereas PCP (2-8 mg/kg s.c.) induced a dose-dependent place preference in mice pretreated with PCP (10 mg/kg/day s.c.) for 28 days. The place preference induced by PCP (8 mg/kg s.c.) was attenuated significantly by α-methyl-p- tyrosine (100 mg/kg i.p.), a tyrosine hydroxylase inhibitor, 6- hydroxydopamine (100 μg/ mouse i.c.v.), a dopaminergic neurotoxin, and R- (+)-7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine (0.5 mg/kg s.c.), a dopamine D1 receptor antagonist. These agents themselves produced neither the place preference nor aversion. In contrast to the attenuating effects of these agents, N-(2-chloroethyl)-N-ethyl-2- bromobenzylamine (30 mg/kg i.p.), a noradrenergic neurotoxin, ritanserin (1 mg/kg i.p.), a serotonin2 receptor antagonist, and (-) sulpiride (50 and 100 mg/kg i.p.), a dopamine D2 receptor antagonist, failed to affect the PCP- induced place preference. In mice pretreated with methamphetamine (1 mg/kg/day s.c.) for 14 days, PCP (8 mg/kg s.c.) induced the place preference, but not aversion. These results demonstrate that the PCP-induced place preference depends on dopaminergic, but not on serotonergic and noradrenergic, neuronal systems and suggest a role for D1 receptors in the mediation of the PCP-induced place preference.",
author = "Yukihiro Noda and Yoshiaki Miyamoto and Takayoshi Mamiya and Hiroyuki Kamei and Hiroshi Furukawa and Toshitaka Nabeshima",
year = "1998",
month = "7",
day = "1",
language = "English",
volume = "286",
pages = "44--51",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "1",

}

Involvement of dopaminergic system in phencyclidine-induced place preference in mice pretreated with phencyclidine repeatedly. / Noda, Yukihiro; Miyamoto, Yoshiaki; Mamiya, Takayoshi; Kamei, Hiroyuki; Furukawa, Hiroshi; Nabeshima, Toshitaka.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 286, No. 1, 01.07.1998, p. 44-51.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Involvement of dopaminergic system in phencyclidine-induced place preference in mice pretreated with phencyclidine repeatedly

AU - Noda, Yukihiro

AU - Miyamoto, Yoshiaki

AU - Mamiya, Takayoshi

AU - Kamei, Hiroyuki

AU - Furukawa, Hiroshi

AU - Nabeshima, Toshitaka

PY - 1998/7/1

Y1 - 1998/7/1

N2 - In the conditioned place preference test, phencyclidine (PCP) produces place aversion in naive rats, whereas PCP produces place preference in rats treated with PCP repeatedly. Although the PCP-induced place aversion is thought to involve the serotonergic system, the mechanisms of the PCP- induced place preference are unclear. We investigated whether the dopaminergic system is involved in place preference induced by PCP in mice repeatedly treated with PCP, because it is well known that the dopaminergic system plays an important role in the rewarding effect of drugs. PCP (2-8 mg/kg s.c.) induced a dose-dependent place aversion in naive mice, whereas PCP (2-8 mg/kg s.c.) induced a dose-dependent place preference in mice pretreated with PCP (10 mg/kg/day s.c.) for 28 days. The place preference induced by PCP (8 mg/kg s.c.) was attenuated significantly by α-methyl-p- tyrosine (100 mg/kg i.p.), a tyrosine hydroxylase inhibitor, 6- hydroxydopamine (100 μg/ mouse i.c.v.), a dopaminergic neurotoxin, and R- (+)-7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine (0.5 mg/kg s.c.), a dopamine D1 receptor antagonist. These agents themselves produced neither the place preference nor aversion. In contrast to the attenuating effects of these agents, N-(2-chloroethyl)-N-ethyl-2- bromobenzylamine (30 mg/kg i.p.), a noradrenergic neurotoxin, ritanserin (1 mg/kg i.p.), a serotonin2 receptor antagonist, and (-) sulpiride (50 and 100 mg/kg i.p.), a dopamine D2 receptor antagonist, failed to affect the PCP- induced place preference. In mice pretreated with methamphetamine (1 mg/kg/day s.c.) for 14 days, PCP (8 mg/kg s.c.) induced the place preference, but not aversion. These results demonstrate that the PCP-induced place preference depends on dopaminergic, but not on serotonergic and noradrenergic, neuronal systems and suggest a role for D1 receptors in the mediation of the PCP-induced place preference.

AB - In the conditioned place preference test, phencyclidine (PCP) produces place aversion in naive rats, whereas PCP produces place preference in rats treated with PCP repeatedly. Although the PCP-induced place aversion is thought to involve the serotonergic system, the mechanisms of the PCP- induced place preference are unclear. We investigated whether the dopaminergic system is involved in place preference induced by PCP in mice repeatedly treated with PCP, because it is well known that the dopaminergic system plays an important role in the rewarding effect of drugs. PCP (2-8 mg/kg s.c.) induced a dose-dependent place aversion in naive mice, whereas PCP (2-8 mg/kg s.c.) induced a dose-dependent place preference in mice pretreated with PCP (10 mg/kg/day s.c.) for 28 days. The place preference induced by PCP (8 mg/kg s.c.) was attenuated significantly by α-methyl-p- tyrosine (100 mg/kg i.p.), a tyrosine hydroxylase inhibitor, 6- hydroxydopamine (100 μg/ mouse i.c.v.), a dopaminergic neurotoxin, and R- (+)-7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine (0.5 mg/kg s.c.), a dopamine D1 receptor antagonist. These agents themselves produced neither the place preference nor aversion. In contrast to the attenuating effects of these agents, N-(2-chloroethyl)-N-ethyl-2- bromobenzylamine (30 mg/kg i.p.), a noradrenergic neurotoxin, ritanserin (1 mg/kg i.p.), a serotonin2 receptor antagonist, and (-) sulpiride (50 and 100 mg/kg i.p.), a dopamine D2 receptor antagonist, failed to affect the PCP- induced place preference. In mice pretreated with methamphetamine (1 mg/kg/day s.c.) for 14 days, PCP (8 mg/kg s.c.) induced the place preference, but not aversion. These results demonstrate that the PCP-induced place preference depends on dopaminergic, but not on serotonergic and noradrenergic, neuronal systems and suggest a role for D1 receptors in the mediation of the PCP-induced place preference.

UR - http://www.scopus.com/inward/record.url?scp=0031846909&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031846909&partnerID=8YFLogxK

M3 - Article

C2 - 9655840

AN - SCOPUS:0031846909

VL - 286

SP - 44

EP - 51

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 1

ER -